Ipsen (Paris:IPN)(Euronext: IPN; ADR: IPSEY) today announced positive initial results from the double-blind phase III study of Dysport® (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport® showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale (MAS). In addition, a statistically significant clinical benefit for the patients treated with Dysport® was demonstrated versus placebo, as measured by the Physician Global Assessment (PGA). The safety profile observed in the study was consistent with the known safety profile of Dysport® in this indication. Comprehensive results from this double-blind study will be disclosed in the next few months at major international congresses.
Marc de Garidel, Chairman and CEO of Ipsen stated: "These clinical results are an important step in our ambition to become a global leader in the treatment of targeted debilitating diseases. Expanding our scope of indications for Dysport® would help us further develop the neurology franchise, notably in the USA."
Claude Bertrand, Executive Vice-President Research & Development and Chief Scientific Officer of Ipsen commented: "Ipsen is very pleased with the initial results of the Dysport® study in Adult Upper Limb spasticity. We believe it should meet the expectations of physicians by potentially providing a new alternative for treating patients suffering from this debilitating condition. We are grateful to the clinicians, caregivers, patients and their families who were involved in this study."